Depression with melancholic features

Overview - The Heavy Veil

A severe subtype of Major Depressive Disorder (MDD) characterized by a near-complete loss of pleasure (anhedonia) in almost all activities. It feels like a heavy, oppressive blanket, distinct from normal sadness. This subtype points towards more significant biological underpinnings.

• Pervasive Anhedonia: The central feature; an inability to find pleasure in anything.
• Diurnal Variation: Mood is characteristically worse in the morning.
• Psychomotor Disturbance: Observable retardation or agitation.
• Sleep: Early morning awakening, typically ≥2 hours before usual.

⭐ Patients with melancholic features often show a more robust response to somatic treatments like electroconvulsive therapy (ECT) and pharmacotherapy (especially TCAs & SNRIs) than to psychotherapy alone.

Diagnosis - Spotting the Signs

Applies if these features are present during the most severe period of a Major Depressive Episode (MDE). The patient must first meet full MDE criteria.

• Gateway Criteria (≥1 Required):

  • Pervasive Anhedonia: Loss of pleasure in virtually all activities.
  • Lack of Mood Reactivity: Mood does not brighten, even temporarily, to positive stimuli.

• Additional Criteria (≥3 Required):

  • Distinct Quality of Mood: Profound despondency or an "empty" mood.
  • Diurnal Variation: Depression is consistently worse in the morning.
  • Sleep: Early morning awakening (at least 2 hours before usual).
  • Psychomotor: Marked psychomotor agitation or retardation.
  • Appetite/Weight: Significant anorexia or weight loss.
  • Guilt: Excessive or inappropriate guilt.

⭐ Melancholic features are a strong predictor of a favorable response to somatic therapies, particularly Electroconvulsive Therapy (ECT).

Pathophysiology - The Biology of Blight

• Monoamine Hypothesis: Core deficiency in key neurotransmitters: Serotonin (↓ 5-HT), Norepinephrine (↓ NE), and Dopamine (↓ DA).
• HPA Axis Dysregulation: Chronic stress leads to hyperactive Hypothalamic-Pituitary-Adrenal axis.
  • ↑ CRH & ↑ Cortisol levels.
  • Glucocorticoid receptor resistance impairs negative feedback.
• Neuroanatomic Changes:
  • ↓ Hippocampal & prefrontal cortex (PFC) volume.
  • ↑ Amygdala activity (fear, anhedonia).

⭐ A hallmark of melancholia is HPA axis hyperactivity, classically demonstrated by the failure to suppress cortisol levels after administering a low dose of dexamethasone (Dexamethasone Suppression Test).

Treatment - Piercing the Gloom

• Pharmacotherapy First: Melancholia often responds better to broader-acting agents.
  • Preferred: Tricyclic Antidepressants (TCAs) or SNRIs (Venlafaxine, Duloxetine) over SSRIs alone.
  • ⚠️ TCAs: Require careful monitoring (cardiac, anticholinergic effects).
• Somatic Therapies: Highly effective for severe or treatment-refractory cases.
  • Electroconvulsive Therapy (ECT): Gold standard for rapid and robust response, especially with psychosis or catatonia.
  • TMS: An alternative neuromodulation technique.
• Psychotherapy: Primarily as an adjunct to biological treatments (e.g., CBT, supportive).

⭐ ECT demonstrates the highest remission rates (often >80%) for depression with severe melancholic or psychotic features, surpassing pharmacotherapy.

electrode placement)

High‑Yield Points - ⚡ Biggest Takeaways

• The core feature is pervasive anhedonia, a near-complete loss of pleasure in all activities.
• Symptoms characteristically show diurnal variation, being significantly worse in the morning.
• Expect profound psychomotor retardation or, less commonly, agitation.
• Early morning awakening (at least 2 hours before usual) is a classic sleep disturbance.
• Patients often express excessive or inappropriate guilt over minor matters.
• Significant anorexia or weight loss is a key vegetative sign.